23andMe releases Simvastatin Medication Insight report

23andMe Holding released a new Simvastatin Medication Insight report as part of its 23andMe+ membership service that reports on a person’s likelihood of experiencing side effects from this commonly prescribed statin drug. The new Medication Insight report is part of a suite of 23andMe reports that examine how a person’s genetics may impact their response to certain medications and their chance of experiencing possible side effects. These are the first and only direct-to-consumer pharmacogenetic reports authorized by the FDA. Under the recent FDA 510(k) clearance, which modifies the labeling of the previously authorized SLCO1B1 Drug Transport report, there is no additional confirmatory testing requirement for this report, and a healthcare provider can use the results from the report to guide care. Simvastatin is a commonly prescribed statin drug used to lower cholesterol in the blood and reduce the risk of heart attacks, strokes, or other heart problems. This new Simvastatin Medication Insight report available for 23andMe+ members looks at how individuals respond to simvastatin, known by the brand names such as Flolipid and Zocor. The insight report provides clear information about whether an individual has an increased chance of experiencing side effects.